Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

bioTheranostics Awarded Medicare Coverage for Breast Cancer Index Molecular Test

October 15, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–bioTheranostics, Inc., a leader in molecular diagnostics for cancer, today announced that its Breast Cancer IndexSM test has been awarded Medicare coverage. The Centers for Medicare and Medicaid Services posted a positive coverage and reimbursement policy after evaluation by Palmetto GBA, the Medicare administrator responsible for the MolDx molecular diagnostic technology…

ISPE Plan To Prevent Drug Shortages Released At Annual Meeting

October 15, 2014 – 5:00 am | Edit Post

TAMPA, Fla., Oct. 15, 2014 /PRNewswire-USNewswire/ — ISPE, the International Society for Pharmaceutical Engineering, released its Drug Shortages Prevention Plan at its 2014 Annual Meeting in Las Vegas, Nevada. Regulators from the European Medicines Agency (EMA), the US…

KLAS Clinical Decision Support Report Ranks Zynx Health No. 1 in Overall Performance

October 15, 2014 – 5:00 am | Edit Post

LOS ANGELES, Oct. 15, 2014 /PRNewswire/ –ZynxCare emerged as the top-ranked solution for overall performance in the plans of care category, according to the results of the recently released KLAS report, “CDS Order Sets and Care Plans 2014: Choosing the Best Option.”

Orexigen Therapeutics, Inc. Pockets $100 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd.

October 15, 2014 – 5:00 am | Edit Post

Milestone Payments Earned by Orexigen Total $100 Million as Contrave (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial LaunchSAN DIEGO, Oct. 15, 2014 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced…

Announcement Regarding Submission Of Tender Offer For Shares In Ambit Biosciences

October 15, 2014 – 5:00 am | Edit Post

TOKYO and SAN DIEGO, Oct. 14, 2014 /PRNewswire/ –On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender…

Inogen To Announce Third Quarter 2014 Results On Tuesday, November 11, 2014

October 15, 2014 – 5:00 am | Edit Post

GOLETA, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) — Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2014 after the close of trading on Tuesday…

San Diego???s Flourishing Industrial Biotech Sector Provides The Backdrop ForBiotechnology Industry Organization (BIO)???s 2014 Pacific Rim Summit On Industrial Biotech & Bioenergy

October 15, 2014 – 5:00 am | Edit Post

With a growing industrial biotech sector that is home to more than 400 biotechnology companies, San Diego is set to host BIOs 2014 Pacific Rim Summit on Industrial Biotech & Bioenergy. San Diego-based industrial biotechnology companies continue to deliver next generation products and innovative technology solutions, many of which will be highlighted during the programming at this years Summit. The…

UBS: Gilead Sciences, Inc. Remains Solid Buy Despite Irish Tax Changes, Price War

October 15, 2014 – 5:00 am | Edit Post

Illumina, Inc. Picks Three Companies For Accelerator Funding Cycle

October 15, 2014 – 5:00 am | Edit Post

Illumina Accelerator Announces Investment in Inaugural Startup ClassInitial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular PathologySAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (ILMN) today announced the selection of three startup companies for the inaugural Illumina Accelerator funding cycle. The…

<i>Harvard Business Review</i> Ranks <b>David Pyott</b> One Of The Top 5 CEOs In The World

October 15, 2014 – 5:00 am | Edit Post

IRVINE, Calif.–(BUSINESS WIRE)–Allergan, Inc.s (NYSE: AGN) (the Company) Chairman of the Board and Chief Executive Officer, David E.I. Pyott, has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total of 832 current CEOs in 30 countries who qualified for consideration by HBR. The complete list, which has been…